Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia

Trial Profile

Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Nilotinib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms NICE-BORA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 10 May 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top